The vehicle of administration, feed or water, and prandial state influence the oral bioavailability of amoxicillin in piglets
AbstractFeed and water components may interact with drugs and affect their dissolution and bioavailability. The impact of the vehicle of administration (feed and water) and the prandial condition of weaner piglets on amoxicillin ´s oral bioavailability was evaluated. First, amoxicillin’s in vitro dissolution and stability in purified, soft, and hard water, as well as release kinetics from feed in simulated gastric and intestinal media were assessed. Then, pharmacokinetic parameters and bioavailability were determined in fasted and fed pigs using soft water, hard water, or feed as vehicles of administration following a b...
Source: Veterinary Research Communications - April 17, 2024 Category: Veterinary Research Source Type: research

Antibiotics Not Associated with Shorter Duration or Reduced Severity of Acute Lower Respiratory Tract Infection
ConclusionsIn this large prospective study in the US primary and urgent care setting, antibiotics had no measurable impact on the severity or duration of cough due to acute LRTI. Patients had unrealistic expectations regarding the duration of LRTI and the effect of antibiotics which should be the target of antibiotic stewardship efforts. (Source: Journal of General Internal Medicine)
Source: Journal of General Internal Medicine - April 15, 2024 Category: Internal Medicine Source Type: research

Antibiotic prescribing patterns in the placement of dental implants in Europe: A systematic review of survey-based studies
CONCLUSIONS: The most commonly prescribed antibiotic both pre- and postoperatively is amoxicillin and, in allergic patients, clindamycin. In Europe, more doses of PAT are being prescribed than suggested by current recommendations. For this reason, more PAT education is needed in educational curricula to promote a more rational use of antibiotics to reduce the occurrence of antimicrobial resistance.PMID:38615255 | DOI:10.4317/medoral.26450 (Source: Medicina Oral, Patologia Oral y Cirugia Bucal)
Source: Medicina Oral, Patologia Oral y Cirugia Bucal - April 14, 2024 Category: ENT & OMF Authors: Á-O Salgado-Peralvo N Kewalramani A P érez-Jardón M P érez-Sayáns M-V Mateos-Moreno L Arriba-Fuente Source Type: research

Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial
ConclusionThe plasma exposure of tegoprazan, M1, 14-hydroxyclarithromycin and bismuth was increased after the coadministration of tegoprazan, clarithromycin, amoxicillin and bismuth. The coadministration exhibited favorable safety and tolerability.Clinical Trials RegistrationCTR20230643. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 13, 2024 Category: Drugs & Pharmacology Source Type: research

A sophisticated virulence repertoire and colistin resistance of Citrobacter freundii ST150 from a patient with sepsis admitted to ICU in a tertiary care hospital in Uganda, East Africa: Insight from genomic and molecular docking analyses
Infect Genet Evol. 2024 Apr 9:105591. doi: 10.1016/j.meegid.2024.105591. Online ahead of print.ABSTRACTSepsis and multidrug resistance comprise a complex of factors attributable to mortality among intensive care unit (ICU) patients globally. Pathogens implicated in sepsis are diverse, and their virulence and drug resistance remain elusive. From a tertiary care hospital ICU in Uganda, we isolated a Citrobacter freundii strain RSM030 from a patient with sepsis and phenotypically tested it against a panel of 16 antibiotics including imipenem levofloxacin, cotrimoxazole and colistin, among others. We sequenced the organism's g...
Source: Infection, Genetics and Evolution - April 11, 2024 Category: Genetics & Stem Cells Authors: Reuben S Maghembe Maximilian A K Magulye Emmanuel Eilu Simon Sekyanzi Abdalah Makaranga Savannah Mwesigwa Eric Katagirya Source Type: research

A sophisticated virulence repertoire and colistin resistance of Citrobacter freundii ST150 from a patient with sepsis admitted to ICU in a tertiary care hospital in Uganda, East Africa: Insight from genomic and molecular docking analyses
Infect Genet Evol. 2024 Apr 9:105591. doi: 10.1016/j.meegid.2024.105591. Online ahead of print.ABSTRACTSepsis and multidrug resistance comprise a complex of factors attributable to mortality among intensive care unit (ICU) patients globally. Pathogens implicated in sepsis are diverse, and their virulence and drug resistance remain elusive. From a tertiary care hospital ICU in Uganda, we isolated a Citrobacter freundii strain RSM030 from a patient with sepsis and phenotypically tested it against a panel of 16 antibiotics including imipenem levofloxacin, cotrimoxazole and colistin, among others. We sequenced the organism's g...
Source: Infection, Genetics and Evolution - April 11, 2024 Category: Genetics & Stem Cells Authors: Reuben S Maghembe Maximilian A K Magulye Emmanuel Eilu Simon Sekyanzi Abdalah Makaranga Savannah Mwesigwa Eric Katagirya Source Type: research

Vonoprazan-amoxicillin dual regimen with < em > Saccharomyces boulardii < /em > as a rescue therapy for < em > Helicobacter pylori < /em > : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Vonoprazan-amoxicillin dual regimen with < em > Saccharomyces boulardii < /em > as a rescue therapy for < em > Helicobacter pylori < /em > : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology : WJG - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Vonoprazan-amoxicillin dual regimen with < em > Saccharomyces boulardii < /em > as a rescue therapy for < em > Helicobacter pylori < /em > : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Vonoprazan-amoxicillin dual regimen with < em > Saccharomyces boulardii < /em > as a rescue therapy for < em > Helicobacter pylori < /em > : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology : WJG - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Vonoprazan-amoxicillin dual regimen with < em > Saccharomyces boulardii < /em > as a rescue therapy for < em > Helicobacter pylori < /em > : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology : WJG - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Vonoprazan-amoxicillin dual regimen with < em > Saccharomyces boulardii < /em > as a rescue therapy for < em > Helicobacter pylori < /em > : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Vonoprazan-amoxicillin dual regimen with < em > Saccharomyces boulardii < /em > as a rescue therapy for < em > Helicobacter pylori < /em > : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research